Y-Intercept (HK)’s Aclaris Therapeutics ACRS Stock Holding History

Y-Intercept (HK)’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-114,806	Closed	-$126K	–	1244
2024 Q2	$126K	Buy	+114,806	New	+$135K	0.01%	1234

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Y-Intercept (HK)'s ACRS Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 114,806 shares — an estimated $126K sold.

Y-Intercept (HK) first reported a position in ACRS in Q2 2024 and held it in 1 quarter. The position peaked at $126K in Q2 2024. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

Y-Intercept (HK) reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
Y-Intercept (HK) sold 114,806 Aclaris Therapeutics shares in Q3 2024, an estimated $126K.
Y-Intercept (HK) first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 1 quarter.
Y-Intercept (HK)'s Aclaris Therapeutics position peaked at $126K in Q2 2024.
81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.